Cyclerion - Logo - Blue.png
Cyclerion Concludes Unsolicited Proposal Is Not in The Best Interest of The Company
22. November 2022 07:00 ET | Cyclerion Therapeutics, Inc.
CAMBRIDGE, Mass., Nov. 22, 2022 (GLOBE NEWSWIRE) -- Cyclerion Therapeutics, Inc. (Nasdaq: CYCN) today announced that the Board of Directors of the Company acting solely by all of its independent and...
Cyclerion - Logo - Blue.png
Cyclerion Therapeutics Announces CY6463 Data Demonstrating Improved Cellular Energetics in Preclinical Models of Mitochondrial Disease
17. Juni 2022 08:00 ET | Cyclerion Therapeutics, Inc.
CY6463 alleviated mitochondrial dysfunction and reduced inflammation in preclinical models of mitochondrial complex 1 deficiency Data provide support for ongoing CY6463 clinical studies in CNS...